Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

BACKGROUND: BPaL, a 6 month oral regimen composed of bedaquiline, pretomanid, and linezolid for treating extensively drug-resistant tuberculosis (XDR-TB) is a potential alternative for at least 20 months of individualized treatment regimens (ITR). The ITR has low tolerability, treatment adherence, a...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Berg, S. E. J., Pelzer, P. T., van der Land, A. J., Abdrakhmanova, E., Ozi, A. Muhammad, Arias, M., Cook-Scalise, S., Dravniece, G., Gebhard, A., Juneja, S., Handayani, R., Kappel, D., Kimerling, M., Koppelaar, I., Malhotra, S., Myrzaliev, B., Nsa, B., Sugiharto, J., Engel, N., Mulder, C., van den Hof, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284025/
https://www.ncbi.nlm.nih.gov/pubmed/34271884
http://dx.doi.org/10.1186/s12889-021-11427-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284025/
https://www.ncbi.nlm.nih.gov/pubmed/34271884
http://dx.doi.org/10.1186/s12889-021-11427-y

Ejemplares similares